Tango Therapeutics, Inc. 8K

Tango Therapeutics, Inc. filed a Form 8-K to furnish a legal opinion from Goodwin Procter LLP validating the issuance of up to $400 million of common stock under its existing shelf registration statement.

On August 11, 2026, Tango Therapeutics, Inc. filed a Form 8-K that included a legal opinion from Goodwin Procter LLP as Exhibit 5.1, confirming that up to $400,000,000 of shares of its common stock to be offered pursuant to a prospectus supplement under its automatically effective Form S-3ASR shelf registration statement (File No. 333-291684) have been duly authorized and, upon future board approval, issuance, and payment of consideration at or above the board-approved minimum price with sufficient authorized shares available, will be validly issued, fully paid, and nonassessable, thereby supporting the company’s at-the-market or similar offering arrangements with a sales agent.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

8K

Source Type

fda

Accession

0001193125-26-344997

Alert Tier

5